A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: Results of a phase II study of the Groupe d'Études des Lymphomes de l'Adulte (GELA)

References

• Wagstaff J, Gregory W M, Swindell R, Crowther D, Lister T A. Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer 1988; 58: 487–492
   PubMed Web of Science ®Google Scholar
• Straus D J, Gaynor J J, Myers J, Merke D P, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173–1186
   PubMed Web of Science ®Google Scholar
• Proctor S J, Taylor P, Donnan P, Boys R, Lennard A, Prescott R J, with members of the Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. A numerical index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Eur J Cancer 1991; 27: 624–629
   PubMed Web of Science ®Google Scholar
• Carella A M, Carlier P, Congiu A, Occhini D, Nati S, Santini G, et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 1991; 8: 99–103
   PubMed Web of Science ®Google Scholar
• Gobbi P G, Comelli M, Grignani G E, Pieresca C, Bertoloni D, Ascari E. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's disease (IDHD). Haematologica 1994; 79: 241–255
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Proctor S J, Mackie M, Levis A, Dawson A, White J, Prescott R J, et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002; 38: 795–806
   PubMed Web of Science ®Google Scholar
• Saghatchian M, Djeridane M, Escoffre-Barbe M, Desablens B, Foussard C, Lacotte-Thierry L, et al. Very high risk Hodgkin's disease (HD): ABVD (4 cycles) plus BEAM followed by autologous stem cell transplantation (ASCT) and radiotherapy (RT) versus intensive chemotherapy (3 cycles) (INT-CT) and RT. Four-year results of the GOELAMS H97-GM multicentric randomized trial. Proc ASCO 2002; A1051
   Google Scholar
• Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21: 2320–2325
   PubMed Web of Science ®Google Scholar
• Bartlett N L, Rosenberg S A, Hoppe R T, Hancock S L, Horning S J. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13: 1080–1088
   PubMed Web of Science ®Google Scholar
• Radford J A, Rohatiner A ZS, Ryder W DJ, Deakin D P, Barbui T, Lucie N P, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20: 2988–2994
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Loeffler M, Diehl V. Rational for dose escalation of first-line conventional chemotherapy in advanced Hodgkin's disease. Ann Oncol 1996; 7: 95–98
   PubMed Web of Science ®Google Scholar
• Fermé C, Diviné M, Lederlin P, Brice P, Caillot D, Gabarre J, , for the Groupe d'Etude des Lymphomes de l'Adulte, et al. A weekly regimen in patients with advanced Hodgkin's disease (HD): response and toxicity analysis in 40 patients. Proc Am Soc Clin Oncol 1998; 17: 9, (Abstr. 31)
   Google Scholar
• World Health Organization. International Histological Classification of Tumours, 2nd edn. World Health Organization, Geneva 1969 – 1981, Berlin: Springer-Verlag, 1988-Present
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Klimo P, Connors J M. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988; 25(Suppl 2)34–40
   PubMed Web of Science ®Google Scholar
• Horning J H, Hoppy R T, Breslin S, Bartlett N L, Brown B W, Rosenberg S A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630–637
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
   PubMed Web of Science ®Google Scholar
• Canellos G P, Anderson J R, Propert K J, Nisjen N, Cooper M R, Henderson E S, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Fermé C, Bastion Y, Brice P, Lederlin P, Divine M, Gabarre J, , for the Groupe d'Etudes des Lymphomes de l'Adulte, et al. Prognosis of patients with advanced Hodgkin's disease. Evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adult study. Cancer 1997; 80: 1124–1133
   PubMed Web of Science ®Google Scholar
• Gobbi P G, Levis A, Chisesi T, Broglia C, Vitolu U, Stelitano C, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23: 198–207
   Web of Science ®Google Scholar
• Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 1734–1739
   PubMed Web of Science ®Google Scholar
• Aleman B MP, Raemaekers J MM, Tirelli U, Bortolus R, van 't Veer M B, Lybeert M L, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396–2404
   PubMed Web of Science ®Google Scholar
• Fermé C, Mounier N, Casasnovas O, Brice P, Divine M, Sonet A, , for the Groupe d'Etude des Lymphomes de l'Adulte, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 107: 4636–4642
   PubMed Web of Science ®Google Scholar